0000000000547883

AUTHOR

Antonino Mazzone

showing 3 related works from this author

Predicting resistant etiology in hospitalized patients with blood cultures positive for Gram-negative bacilli

2018

Abstract Objective To develop a risk-scoring tool to predict multidrug-resistant (MDR) etiology in patients with bloodstream infections (BSI) caused by Gram-negative bacilli (GNB). Methods A prospective multicenter study analyzed patients with BSI hospitalized in 31 Internal Medicine wards in Italy from March 2012 to December 2012. Patients with BSI caused by MDR-GNB (non-susceptible to at least one agent in three antimicrobial categories) were compared to those with BSI due to susceptible GNB. A logistic regression to identify predictive factors of MDR-GNB was performed and the odds ratio (OR) were calculated. A score to predict the risk of MDR was developed. Results Of 533 BSI episodes, 2…

Male0301 basic medicineMultivariate analysisGram-negative bacilliHospitalized patientsLogistic regressionLikelihood ratios in diagnostic testingRisk FactorsDrug Resistance Multiple BacterialMedicineAge FactorMultidrug-resistantProspective StudiesMultivariate AnalysiAged 80 and overAge FactorsAnti-Bacterial AgentsHospitalizationItalyBloodstream infections; Gram-negative bacilli; Multidrug-resistantBloodstream infections; Gram-negative bacilli; Multidrug-resistant; Internal MedicineFemaleSettore SECS-S/01 - StatisticaHumanmedicine.medical_specialtyLogistic Model030106 microbiologyBloodstream infection03 medical and health sciencesInternal medicineAnti-Bacterial AgentGram-Negative BacteriaGram-Negative Bacterial InfectionInternal MedicineHumansAgedbusiness.industryRisk FactorGram negative bacilliOdds ratiomedicine.diseaseProspective StudieLogistic ModelsROC CurveBlood CultureBacteremiaMultivariate AnalysisEtiologyBloodstream infectionsGram-Negative Bacterial Infectionsbusiness
researchProduct

High prevalence of fragility vertebral fractures in patients hospitalised in Internal Medicine Units. Results of the POINT (Prevalence of Osteoporosi…

2015

Abstract Background Osteoporotic vertebral fractures (VFs) often go unrecognised in both healthy individuals and in pathological conditions. Few data exist on VFs in patients hospitalised in Internal Medicine Units (IMUs), who often suffer from multiple concomitant chronic disorders. Aim of the study This multicentre cross-sectional study was aimed at assessing the prevalence of VFs in an unselected population of patients referring to IMUs. Correlations between VFs and the main coexisting diseases were also investigated. Methods Information on demographic, clinical and laboratory findings, and on the presence of known risk factors for osteoporosis was recorded. The Genant's semi-quantitativ…

Malemedicine.medical_specialtyHistologyPhysiologyEndocrinology Diabetes and MetabolismOsteoporosisPrevalenceVery frequentEndocrinologyInternal medicineInternal MedicinePrevalenceMedicineHumansIn patientvertebral fracturesPathologicalAgedDemographybusiness.industryMiddle Agedmedicine.diseaseComorbidityinternal medicine; osteoporosis; vertebral fracturesosteoporosisSpineHospitalizationDiabetes and Metabolisminternal medicineLogistic ModelsConcomitantVertebral fracturesCohortMultivariate AnalysisOsteoporosis vertebral fractures Genant's semi-quantitative methodOsteoporosisSpinal FracturesFemaleInternal medicine; Osteoporosis; Vertebral fractures; Aged; Demography; Female; Hospitalization; Humans; Internal Medicine; Logistic Models; Male; Middle Aged; Multivariate Analysis; Osteoporosis; Prevalence; Spinal Fractures; Spine; Endocrinology Diabetes and Metabolism; Histology; Physiologybusiness
researchProduct

Additional file 1 of Real-world evidence of biologic treatments in psoriatic arthritis in Italy: results of the CHRONOS (EffeCtiveness of biologic tr…

2022

Additional file 1: Socio-demographic and clinical characteristics at enrollment/start of biologic treatment under analysis (in Secukinumab and TNFis patients). In this file main socio-demographic and clinical characteristics at enrollment/start of biologic treatment under analysis are described in the groups of patients treated with Secukinumab and with TNFis.

researchProduct